Navigation Links
VaxGen and Raven Terminate Merger Agreement
Date:3/28/2008

SOUTH SAN FRANCISCO, Calif., March 28 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, announced that the Company and Raven biotechnologies, inc. have mutually agreed to terminate their merger agreement in light of stronger than anticipated opposition to the proposed merger by VaxGen stockholders. In addition, VaxGen's Board has withdrawn from stockholder consideration the proposed 2008 Equity Incentive Plan, which is unnecessary in the absence of the merger. It has recently become apparent to both companies that despite initial indications to the contrary, the proposed merger and related equity plan proposals would be rejected by VaxGen stockholders.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )

"We are obviously very disappointed that the proposed merger with Raven was not approved by our stockholders," said James P. Panek, VaxGen President and CEO. "Despite the strong support of some institutions, and solid support by so many individual investors, it has become quite clear that there is sufficient opposition, such that this merger will not be approved."

VaxGen intends to open the Special Meeting of Stockholders scheduled for Friday, March 28th, but will adjourn the meeting without taking any action. The Board of Directors intends to immediately assess the Company's strategic alternatives, including a possible liquidation of the Company.

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the holding of the Special Meeting of Stockholders and the Board of Directors' plans to assess strategic alternatives. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Additional information concerning these and other risk factors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward- looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.


'/>"/>
SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VaxGen Issues Rebuttal to MedCap Letter
2. VaxGen Common Stock Now Quoted on OTC Bulletin Board
3. VaxGen Reports Financial Update
4. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
5. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
6. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
7. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
8. VaxGen Addresses MPM Claims in Letter to Stockholders
9. VaxGen Files Last Outstanding Periodic Report With SEC
10. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
11. VaxGen Files First Quarter 2007 Financials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... NEW YORK , May 2, 2016 ... company announces that its technology partner Mannin Research Inc. ... and Ophthalmology (ARVO), which takes place from May 1-5, ... Research executives will be meeting with its vendors and ... further explore business development goals and other collaborative opportunities ...
(Date:4/29/2016)... Irvine, CA (PRWEB) , ... April 29, 2016 ... ... research leader in personalized pain medicine, is excited to announce the launch of ... to supporting public health studies, volunteerism, and education to promote the use of ...
(Date:4/29/2016)... ... ... Intelligent Implant Systems announced today that the two-level components for the Revolution™ Spinal ... These components expand the capabilities of the system and allow Revolution™ to be ... 2015, the company has seen significant sales growth in 1Q 2016, and the system ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next week on ... on its first-in-class technologies for tissue stem cell counting and expansion to gene-editing ... to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/17/2016)... 17, 2016 ABI Research, the leader ... global biometrics market will reach more than $30 ... from 2015. Consumer electronics, particularly smartphones, continue to ... anticipated to reach two billion shipments by 2021 ... Pavlakis , Research Analyst at ABI Research. "Surveillance ...
Breaking Biology News(10 mins):